AnaCardio

AnaCardio

Private
StockholmHealthcare & Life Scienceshttps://anacardio.com

Last Round

Series A

Extension

Jan 9, 2025

Est. Valuation

$1.71M

Total Funding Raised

$33.16M

Momentum Score

50 /100

Company Overview

AnaCardio is a clinical-stage biopharmaceutical company that develops novel drugs to treat heart failure.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Clinical Trials, Drug Discovery

Business Model

B2B

Customer Profile

Revenue Share

AI Layer

Non-AI

Keywords

heart failure drugsheart failure with reduced ejection fractionHFrEFghrelin receptor agonistfirst-in-class drugclinical-stage biopharmacardiac contractilityinotropesmall-molecule drugoral therapycardiovascular drugscalcium sensitizernovel therapeuticsdrug developmentpharma licensing

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

AnaCardio Comps

Public and private peers based on sector, stage, and business model.

CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

AnaCardio Funding Rounds

Historical fundraising activity

RoundDateAmount RaisedValuationInvestorsSources
Series A ExtensionJan 9, 2025
Series ASep 8, 2022
VC RoundFeb 3, 2022
SeedJun 17, 2021

Key People

Founding team and executive leadership

Philipp Mathieu

Chief Financial Officer

Executive Team

Johan Sjödahl

Chief Operating Officer

Executive Team

AnaCardio Investors

Notable investors and investment history

InvestorRounds
IndustrifondenSeries A Extension, VC Round, Series A
Novo HoldingsSeries A Extension
Karolinska Development ABSeries A
Pureos BioventuresSeries A Extension
Flerie ABSeries A Extension
Sound BioventuresSeries A Extension

Market signals

Structured signals derived from secondary market and firmographic data.

  • May 15, 2026

    Monthly visitors increased 31% MoM.

  • Mar 26, 2026

    AC01 study selected for Late-Breaking Science at Heart Failure 2026 Congress.

AnaCardio Filings

SEC and related filings with document metadata.

TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

AnaCardio Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about AnaCardio's valuation, stock price, and market status.

Firmographic Details

HeadquartersStockholm
Employee Range26
Year Founded2017
Last FundingJan 9, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.







Disclaimer All investments involve risk, including the risk of loss of principal. You should carefully consider your investment objectives, risks, transaction costs and other expenses before deciding to invest in options, swaps or other investments.This does not constitute an offer by Caplight Technologies, Inc. to sell, or a solicitation of an offer to buy, any securities and may not be used or relied upon in connection with any offer or sale of securities. An offer or solicitation can be made only through the delivery of final offering document(s) and purchase agreement(s), and will be subject to the terms and conditions and risks delivered in such documents. Any securities offered are offered through Caplight Markets LLC, member FINRA/SIPC.